Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

4R3O

Human Constitutive 20S Proteasome

Summary for 4R3O
Entry DOI10.2210/pdb4r3o/pdb
Related1IRU 1PMA 1RYP 3UNE 4R67
DescriptorProteasome subunit alpha type-6, Proteasome subunit beta type-3, Proteasome subunit beta type-2, ... (15 entities in total)
Functional Keywordshydrolase
Biological sourceHomo sapiens (human)
More
Cellular locationCytoplasm: P60900 P49720 P49721 P28074 P20618 P28070 P25787 P25789 O14818 P28066 P25786 P25788 P28072 Q99436
Total number of polymer chains28
Total formula weight697897.01
Authors
Sacchettini, J.C.,Harshbarger, W.H. (deposition date: 2014-08-16, release date: 2015-01-28, Last modification date: 2024-02-28)
Primary citationHarshbarger, W.,Miller, C.,Diedrich, C.,Sacchettini, J.
Crystal Structure of the Human 20S Proteasome in Complex with Carfilzomib.
Structure, 23:418-424, 2015
Cited by
PubMed Abstract: Proteasome inhibition is highly effective as a treatment for multiple myeloma, and recently carfilzomib was granted US FDA approval for the treatment of relapsed and refractory multiple myeloma. Here, we report the X-ray crystal structure of the human constitutive 20S proteasome with and without carfilzomib bound at 2.9 and 2.6 Å, respectively. Our data indicate that the S3 and S4 binding pockets play a pivotal role in carfilzomib's selectivity for chymotrypsin-like sites. Structural comparison with the mouse immunoproteasome crystal structure reveals amino acid substitutions that explain carfilzomib's slight preference for chymotrypsin-like subunits of constitutive proteasomes. In addition, comparison of the human proteasome:carfilzomib complex with the mouse proteasome:PR-957 complex reveals new details that explain why PR-957 is selective for immunoproteasomes. Together, the data presented here support the design of inhibitors for either constitutive or immunoproteasomes, with implications for the treatment of cancers as well as autoimmune and neurodegenerative diseases.
PubMed: 25599644
DOI: 10.1016/j.str.2014.11.017
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.6 Å)
Structure validation

227344

PDB entries from 2024-11-13

PDB statisticsPDBj update infoContact PDBjnumon